Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine…

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into…

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…

A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D.,…

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…

The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…

Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…